-
Angiotech Pharmaceuticals (Vancouver, British Columbia) reported that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has expired pertaining to the proposed grant of an exclusive license to Boston Scientific (Natick, Massachusetts) with respect to the use of paclitaxel and other agents on medical devices in the coronary vascular field of use.
-
The annual scientific sessions of the American Heart Association (AHA; Dallas) primarily feature broad platforms for new product rollouts, an avalanche of clinical trials and even, occasionally, some interesting debate.
-
CryoCath Technologies (Montreal), a company developing cryotherapy products to treat cardiovascular disease, reported that its Freezor MAX catheter has received a supplemental premarket approval (PMA) indication from the FDA, allowing it to launch its fifth product into the U.S.
-
-
-
-
Eric Topol, MD, chief academic officer of the Cleveland Clinic, said during the Clinic-sponsored Medical Innovation Summit here in mid-October that those involved with or interested in innovation need to get away from the idea that every drug and device needs to be a blockbuster product.
-
E-Z-EM (Lake Success, New York) reported that the spin-off of its AngioDynamics subsidiary has been completed. On Oct. 30, E-Z-EM distributed 0.856377 of a share of AngioDynamics common stock as a dividend on each outstanding share of E-Z-EM common stock to E-Z-EM shareholders of record as of Oct. 11. E-Z-EM shareholders received cash in lieu of any fractional shares.
-
Arrow International (Reading, Pennsylvania) reported the promotion of several executives to positions of new responsibility and the retirement of Philip Fleck, president and chief operating officer, effective Dec. 31.
-
American women are one step closer to having a contraceptive implant option with the recent Food and Drug Administration (FDA) issuance of approvable status for Implanon, the single-rod contraceptive implant from Organon (West Orange, NJ).
